AUTH/1982/3/07: Anonymous v Teva — Qvar journal advertisement (no breach)

📅 2007 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/1982/3/07
PartiesAnonymous v Teva
ProductQvar (beclomethasone diproprionate)
MaterialJournal advertisement in Pulse (ref IV/QV/AD/02/07)
Main issueUse of partially clothed people; alleged to undermine serious nature of medicines and disrespect HCP audience
Applicable Code year2006
Clauses considered9.1 and 9.2
DecisionNo breach
Complaint received29 March 2007
Case completed27 April 2007
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous reader complained about a Teva UK Limited journal advertisement for Qvar (beclomethasone diproprionate) published in Pulse (ref IV/QV/AD/02/07).
  • The complaint alleged the ad prominently displayed partially clothed individuals and used this to attract attention.
  • The complainant said the approach undermined the serious nature of medicines, disrespected the professional audience, could offend some readers, and reflected negatively on the industry.
  • The PMCPA asked Teva to respond under Clauses 9.1 and 9.2 (Code year 2006).
  • Teva said the main focus was a beach holiday scene dominated by a man in swim shorts blowing up a lilo, intended to convey that good asthma control enables normal activities.
  • Teva cited pre-publication market research (12 GPs and 12 nurses) indicating the beach concept was preferred and not considered offensive or undermining.
  • Teva stated similar imagery appeared in other healthcare publications and was not markedly different from other ads.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clause 9.2 (special nature of medicines / professional standing of audience).
  • No breach of Clause 9.1 (high standards must be maintained at all times).
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training